证券代码：688076 证券简称：诺泰生物 转债代码：118046 转债简称：诺泰转债 江苏诺泰澳赛诺生物制药股份有限公司 2024 年第二次临时股东大会会议资料 二零二四年十一月 | 2024 | 年第二次临时股东大会会议资料目录 1 | | --- | --- | | 2024 | 年第二次临时股东大会会议须知 2 | | 2024 | 年第二次临时股东大会会议议程 4 | | | 议案一：关于续聘会计师事务所的议案 6 | | | 议案二：关于修订《公司章程》及其附件的议案 10 | | | 章 程 25 | | | 股东大会议事规则 69 | | | 董事会议事规则 83 | | | 监事会议事规则 93 | 江苏诺泰澳赛诺生物制药股份有限公司（688076） 2024 年第二次临时股东大会会议资料 江苏诺泰澳赛诺生物制药股份有限公司 2024 年第二次临时股东大会会议须知 为保障江苏诺泰澳赛诺生物制药股份有限公司（下称"公司"）全体股东 的合法权益，维护股东大会的正常秩序，保证股东大会如期、顺利召开。根据 《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》 《江苏诺泰澳赛诺生物 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [5][17]. Core Views - The company has demonstrated impressive performance with a significant increase in profitability, as evidenced by a revenue of 1.252 billion yuan (+76.51%) and a net profit of 350 million yuan (+281.90%) for the first three quarters of 2024 [1][2]. - The growth in revenue is primarily driven by the rapid increase in sales of peptide raw materials, with profit growth outpacing revenue growth due to economies of scale and a higher proportion of high-margin products [1][2]. - The company is expanding its peptide production capacity, with plans to reach an annual capacity of 10 tons by the end of 2025, which is expected to further enhance its market position [3]. Financial Performance Summary - For the first three quarters of 2024, the company achieved a gross margin of 69.32% (+8.63 percentage points), reflecting improved profitability due to scale effects and a higher proportion of high-margin products [2]. - The company’s net profit margin reached 27.97% (+15.04 percentage points), indicating a significant enhancement in profitability [2]. - The company has increased its R&D expense ratio to 13.80% (+1.76 percentage points) as part of its strategy to build technological barriers [2]. Earnings Forecast and Financial Metrics - The company’s revenue is projected to grow to 1.738 billion yuan in 2024, representing a year-on-year increase of 68% [4]. - The forecasted net profit for 2024 is 469 million yuan, reflecting a substantial growth rate of 187.6% compared to the previous year [4]. - The expected earnings per share (EPS) for 2024 is 2.13 yuan, with a projected PE ratio of 24.3x [4][15].

Investment Rating - The investment rating for the company is "Accumulate" [3][16]. Core Views - The report highlights that the peptide products are experiencing continuous growth, and capacity construction is accelerating, indicating a positive long-term growth outlook [2]. - The revenue for Q1-Q3 2024 reached 1.252 billion yuan, representing a year-on-year increase of 76.51%, while the net profit attributable to the parent company was 350 million yuan, up 281.90% year-on-year [7]. - The report anticipates that the demand for terminal peptide products will exceed expectations, leading to an upward revision of the EPS forecasts for 2024-2026 [7]. Financial Summary - Revenue for 2024 is projected to be 1.653 billion yuan, with a year-on-year growth of 59.9% [8]. - The net profit attributable to the parent company for 2024 is expected to be 436 million yuan, reflecting a significant increase of 167.7% [8]. - The EPS for 2024 is forecasted at 1.98 yuan, with subsequent years showing continued growth to 2.67 yuan in 2025 and 3.50 yuan in 2026 [7][8]. Capacity Expansion - The company is set to complete the construction of a new peptide workshop by the end of 2024, which will increase the peptide production capacity to 5 tons per year [7]. - A second peptide workshop is expected to be completed in the first half of 2025, adding another 5 tons per year to the production capacity [7]. Market Position - The company has received FDA First Adequate Letters for its raw materials, which will facilitate compliance with global regulatory requirements [7]. - The report notes that the company has secured a contract worth 102 million USD with a large European pharmaceutical company, with deliveries expected to accelerate in the second half of 2024 [7].

本周累计10家上市公司公告公司或相关方被立案 公告次日诺泰生物盘中逼近20CM跌停 财联社10月27 日电，据财联社不完全统计，截至发稿，本周（10.21-10.27）包括华闻集团、宁波方正、ST华微、广济 药业、南卫股份、盈方微、诺泰生物、人福医药、中船应急和四环生物在内的10家A股上市公司公告公 司或相关方被证监会立案调查。 其中，因涉嫌内幕交易或涉嫌泄露内幕信息，南卫股份、盈方微相关方被证监会立案。 二级市场表现来看，公告次日诺泰生物盘中逼近20CM跌停，中船应急收跌近12%。 ...

中诚信国际认为，上述事项反映了公司在信息披露等规范运作方面可能存 北京市东城区朝阳门内大街南竹杆胡同 2 号银河 SOHO5 号楼 邮编：100010 电话：（8610）6642 8877 传真：（8610）6642 6100 Building 5, Galaxy SOHO, No.2 Nanzhuganhutong,ChaoyangmenneiAvenue, Dongcheng District,Beijing, 100010 在一定不足，但尚未对企业信用水平产生重大不利影响。中诚信国际将持续跟踪 中国证监会对本次立案调查的最终结论及该事项其他后续进展情况，同时将在 上述债券存续期内对公司的内部控制及信息披露情况保持关注，并及时评估相 关事项可能对公司整体信用状况产生的影响。 特此公告 China Chengxin International Credit Rating Co.,Ltd. [2024]378 中诚信国际关于关注江苏诺泰澳赛诺生物制药股份有限公司及实际控 制人之一收到中国证券监督管理委员会立案告知书的公告 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"诺泰生物"或"公司"） 及其发行的"诺泰转 ...

诺泰生物（688076.SH） 医疗服务 证券研究报告/公司点评报告 2024 年 10 月 24 日 业绩超过预告中枢，毛利率显著提升，全年高增有望持续 | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------------------------------------------------------------------- ...

转债代码：118046 转债简称：诺泰转债 证券代码：688076 证券简称：诺泰生物 江苏诺泰澳赛诺生物制药股份有限公司 投资者关系活动记录表 编号：2024-004 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------|---------|--------------------------------------------------------------------------|---------|------------------------------------|-------|-------|-------|---------------------| | 投资者关系活动 \n类别 | \n \n | 特定对象调研 \n业绩说明会 \n现场参观 | \n \n | 分析师会议 \n新闻发布会 \n其他 | \n | | | 媒体采访 \n路演活动 | | 参与单位名称及 | | 网上投资者 | | | | | | | | 人员姓名 | | | | | | | | | | 时间 | ...

| 证券代码：688076 | 证券简称：诺泰生物 | 公告编号：2024-093 | | --- | --- | --- | | 转债代码：118046 | 转债简称：诺泰转债 | | 江苏诺泰澳赛诺生物制药股份有限公司 关于累计新增借款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）根据《上海证 券交易所上市公司自律监管指引第 12 号——可转换公司债券》等相关规定，现 就公司 2024 年累计新增借款情况公告如下： 一、主要财务数据概况 截至2023年末，公司经审计归属于上市公司股东的净资产为217,026.83万 元，借款余额（合并报表口径、借款本金，下同）为58,527.06万元。截至2024 年10月24日，公司借款余额（未经审计，下同）为134,930.37万元，其中：2024 年1月1日至2024年10月24日累计新增借款金额为138,278.77万元，占2023年末 归属于上市公司股东的净资产63.72%，同时本年度累计偿还贷款61,875.4 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has maintained high growth in the first three quarters, with a revenue increase of 76.51% year-on-year, reaching 12.52 billion yuan, and a net profit of 3.55 billion yuan, up 301.43% [1][2] - The gross profit margin improved to 61.0%, and the net profit margin increased to 28.01%, reflecting strong profitability [2] - The company is actively expanding its global market presence, having signed significant strategic cooperation agreements in various regions, including Europe, North America, and India, which will support future growth [3] - The company is advancing its production capacity for peptide APIs, with a new facility expected to reach a capacity of 10 tons per year by the end of 2025 [4] Financial Performance Summary - Revenue for 2024 is projected to be 1.738 billion yuan, with a year-on-year growth of 68.1% [5] - The net profit for 2024 is estimated at 461 million yuan, representing a year-on-year increase of 182.7% [5] - The earnings per share (EPS) for 2024 is forecasted to be 2.10 yuan, with a price-to-earnings (P/E) ratio of 28.9 [5] - The company’s total market capitalization is 133.25 billion yuan, with a circulating market capitalization also at 133.25 billion yuan [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：688076 | 证券简称：诺泰生物 | 公告编号：2024-092 | | --- | --- | --- | | 转债代码：118046 | 转债简称：诺泰转债 | | 江苏诺泰澳赛诺生物制药股份有限公司 关于公司及实际控制人之一收到中国证券监督管理委员会 立案告知书的公告 公司将积极配合中国证监会的相关工作，并严格按照监管要求履行信息披露 义务。 目前公司的经营情况正常。公司相关信息以公司在指定信息披露媒体刊登或 发布的公告为准，敬请广大投资者理性投资，注意投资风险。 特此公告。 江苏诺泰澳赛诺生物制药股份有限公司董事会 2024 年 10 月 24 日 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）及实际控制人 之一赵德中于近日收到中国证券监督管理委员会（以下简称"中国证监会"）《立 案告知书》（证监立案字 0382024093 号、证监立案字 0382024094 号）。根据《立 案告知书》，因涉嫌信息披露违法违规等，根据《中华人民共和国证券法》《 ...